Todd Anthony
Overview
Explore the profile of Todd Anthony including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaidarov I, Komori H, Stepniak D, Bruinsma K, Dang H, Chen X, et al.
FEBS Open Bio
. 2024 Nov;
15(1):108-121.
PMID: 39564958
Etrasimod (ADP334) is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune-mediated...
2.
Gaidarov I, Adams J, Frazer J, Anthony T, Chen X, Gatlin J, et al.
Cell Signal
. 2018 Jun;
50:9-24.
PMID: 29928987
Angiotensin (1-7) has been reported to be a ligand for the GPCR MAS1. Small molecule MAS1 modulators have also been recently characterized. Aside from convincing evidence for MAS1 activation of...
3.
Gaidarov I, Anthony T, Gatlin J, Chen X, Mills D, Solomon M, et al.
Pharmacol Res
. 2018 Feb;
131:185-198.
PMID: 29471103
GPR84 is an orphan G-protein coupled receptor, expressed on monocytes, macrophages and neutrophils and is significantly upregulated by inflammatory stimuli. The physiological role of GPR84 remains largely unknown. Medium chain...
4.
Buzard D, Lopez L, Moody J, Kawasaki A, Schrader T, Kasem M, et al.
ACS Med Chem Lett
. 2014 Dec;
5(12):1334-9.
PMID: 25516794
S1P1 is a validated target for treatment of autoimmune disease, and functional antagonists with superior safety and pharmacokinetic properties are being sought as second generation therapeutics. We describe the discovery...
5.
Buzard D, Kim S, Lopez L, Kawasaki A, Zhu X, Moody J, et al.
ACS Med Chem Lett
. 2014 Dec;
5(12):1313-7.
PMID: 25516790
APD334 was discovered as part of our internal effort to identify potent, centrally available, functional antagonists of the S1P1 receptor for use as next generation therapeutics for treating multiple sclerosis...
6.
Gaidarov I, Chen X, Anthony T, Maciejewski-Lenoir D, Liaw C, Unett D
Cell Signal
. 2013 Jun;
25(10):2003-16.
PMID: 23770183
Until recently, the anti-atherosclerotic effects of niacin were attributed primarily to its lipid modification properties mediated by adipocyte G-protein coupled receptor GPR109A, though recent studies have raised significant doubts about...